Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Prostaglandin EP3 Receptor Antagonists May Provide Novel Treatment for Diabetes.

Literature DB >> 26101562

Prostaglandin EP3 Receptor Antagonists May Provide Novel Treatment for Diabetes.

Ahmed F Abdel-Magid¹.

Abstract

Entities: Disease Gene

Year: 2015 PMID： 26101562 PMCID： PMC4468410 DOI： 10.1021/acsmedchemlett.5b00188

Source DB: PubMed Journal: ACS Med Chem Lett ISSN： 1948-5875 Impact factor: 4.345

× No keyword cloud information.

2 in total

1. The EP3 Receptor: Exploring a New Target for Type 2 Diabetes Therapeutics.

Authors: Joshua C Neuman; Michelle E Kimple
Journal: J Endocrinol Diabetes Obes Date: 2013 Jul-Sep

2. Prostaglandin E2 receptor, EP3, is induced in diabetic islets and negatively regulates glucose- and hormone-stimulated insulin secretion.

Authors: Michelle E Kimple; Mark P Keller; Mary R Rabaglia; Renee L Pasker; Joshua C Neuman; Nathan A Truchan; Harpreet K Brar; Alan D Attie
Journal: Diabetes Date: 2013-01-24 Impact factor: 9.461

2 in total

1. Human Islet Expression Levels of Prostaglandin E₂ Synthetic Enzymes, But Not Prostaglandin EP3 Receptor, Are Positively Correlated with Markers of β-Cell Function and Mass in Nondiabetic Obesity.

Authors: Nathan A Truchan; Rachel J Fenske; Harpreet K Sandhu; Alicia M Weeks; Chinmai Patibandla; Benjamin Wancewicz; Samantha Pabich; Austin Reuter; Jeffrey M Harrington; Allison L Brill; Darby C Peter; Randall Nall; Michael Daniels; Margaret Punt; Cecilia E Kaiser; Elizabeth D Cox; Ying Ge; Dawn B Davis; Michelle E Kimple
Journal: ACS Pharmacol Transl Sci Date: 2021-06-16

2. Prostaglandin EP3 receptor signaling is required to prevent insulin hypersecretion and metabolic dysfunction in a non-obese mouse model of insulin resistance.

Authors: Jaclyn A Wisinski; Austin Reuter; Darby C Peter; Michael D Schaid; Rachel J Fenske; Michelle E Kimple
Journal: Am J Physiol Endocrinol Metab Date: 2021-07-06 Impact factor: 4.310

2 in total

Prostaglandin EP3 Receptor Antagonists May Provide Novel Treatment for Diabetes.

1. The EP3 Receptor: Exploring a New Target for Type 2 Diabetes Therapeutics.

2. Prostaglandin E2 receptor, EP3, is induced in diabetic islets and negatively regulates glucose- and hormone-stimulated insulin secretion.

1. Human Islet Expression Levels of Prostaglandin E2 Synthetic Enzymes, But Not Prostaglandin EP3 Receptor, Are Positively Correlated with Markers of β-Cell Function and Mass in Nondiabetic Obesity.

2. Prostaglandin EP3 receptor signaling is required to prevent insulin hypersecretion and metabolic dysfunction in a non-obese mouse model of insulin resistance.

1. Human Islet Expression Levels of Prostaglandin E₂ Synthetic Enzymes, But Not Prostaglandin EP3 Receptor, Are Positively Correlated with Markers of β-Cell Function and Mass in Nondiabetic Obesity.